Shares of Torrent Pharmaceuticals Ltd surged 3% on 5 December after the company announced acquiring three brands from Germany-based Boehringer Ingelheim GmbH. 

In its regulatory filing, the company said, “We have entered into an agreement to acquire brands Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin) from Boehringer Ingelheim International GmbH (BI).”

The transaction is expected to be completed in March 2025. 

Since 2022, the company has promoted these brands as part of a continuing co-marketing agreement with Boehringer Ingelheim India.

Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor that is recommended for glycemic management in adults with type 2 diabetes mellitus.

The company’s net profit increased by 40% to Rs 460 crore in the quarter that ended in September 2024.

Earlier in November,  The US Food and Drug Administration (USFDA) sent the business an Establishment Inspection Report (EIR) for its Pithampur plant in Madhya Pradesh. 

At 10:47 am, the shares of Torrent Pharma were trading 0.13%  higher at Rs 3,357.15 on NSE.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!